Skip to main content

Scheduled maintenance

Location search will not be available from Sunday, April 12 at 9:00 PM EDT until Sunday, April 12 at 11:00 PM EDT due to planned site maintenance. We apologize for any inconvenience.

Hide
Quest Diagnostics

Identifying Prediabetic Patients Using Administrative Claims Linked With Lab Data To Assess Progression To Type 2 Diabetes

ISPOR 2024

International Society for Pharmacogenomics and Outcomes Research

Atlanta, GA, May 5-8, 2024

Poster presentation: Identifying Prediabetic Patients Using Administrative Claims Linked With Lab Data To Assess Progression To Type 2 Diabetes

Authors: Ip Q, Wu X, Chin A, Pham N, Rehan W

Specialty: Cardiology, Endocrinology

Related content

On-Demand Webinar
Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Publication
Predictors of lack of glycemic control in persons with type 2 diabetes
Publication
Impact of a Digital Diabetes Prevention Program on Risk factors for Chronic Disease in a Workforce Cohort
Publication
Prognostic value of insulin resistance and hyperglycemia biomarkers for long-term risks of cardiometabolic outcomes

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.